Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on AnaptysBio and keeping the price target at $95.00.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Joseph Pantginis has given his Buy rating due to a combination of factors tied to both litigation clarity and underlying asset value. He believes the completion of the four-day Jemperli trial meaningfully advances resolution of a major uncertainty, with a court decision expected around late 2026 or early 2027, while Jemperli royalties and the GSK partnership continue under the current agreement.

Pantginis also views AnaptysBio’s legal position as well-supported by documentation from the 2020 amendment negotiations and by indications that GSK may have emphasized its ADC portfolio over fully maximizing Jemperli. In his view, this strengthens AnaptysBio’s case without disrupting ongoing development efforts, justifying a continued Buy rating and an unchanged $95 price target.

According to TipRanks, Pantginis is a 5-star analyst with an average return of 23.5% and a 55.91% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Rigel, Iovance Biotherapeutics, and Kura Oncology.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.